Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52.
Saved in:
| Title: | Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52. |
|---|---|
| Authors: | Bachert, Claus1,2,3 (AUTHOR) Claus.Bachert@ugent.be, Khan, Asif H.4 (AUTHOR), Lee, Stella E.5 (AUTHOR), Hopkins, Claire6 (AUTHOR), Peters, Anju T.7 (AUTHOR), Fokkens, Wytske8 (AUTHOR), Praestgaard, Amy9 (AUTHOR), Radwan, Amr10 (AUTHOR), Nash, Scott11 (AUTHOR), Jacob‐Nara, Juby A.12 (AUTHOR), Deniz, Yamo11 (AUTHOR), Rowe, Paul J.12 (AUTHOR) |
| Source: | International Forum of Allergy & Rhinology. Mar2024, Vol. 14 Issue 3, p668-678. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
